



4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0168]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled, “Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, PRASStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: On January 15, 2015, the Agency submitted a proposed collection of information entitled, “Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements” to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

OMB has now approved the information collection and has assigned OMB control number 0910-0785. The approval expires on May 31, 2018. A copy of the supporting statement for this information collection is available on the Internet at

<http://www.reginfo.gov/public/do/PRAMain>.

Dated: May 29, 2015.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2015-13473 Filed: 6/2/2015 08:45 am; Publication Date: 6/3/2015]